U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018050) titled 'Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma' on June 04.
Brief Summary: The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed or Refractory Multiple Myeloma
Intervention:
DRUG: QLS32015
QLS32015 will be administered subcutaneously
DRUG: Pomalidomide
Pomalidomid...